Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study

Genes
Julia E C van SteenhovenThijs van Dalen

Abstract

In this study, in estrogen receptor positive (ER+) early stage breast cancer patients who were considered candidates for 70-gene signature (70-GS, "MammaPrint") use, we compared molecular subtyping (MS) based on the previously validated 80-gene signature (80-GS, "BluePrint") versus surrogate pathological subtyping (PS). Between 1 January 2013 and 31 December 2015, 595 clinical intermediate risk ER+ early stage breast cancer patients were enrolled. Hormone receptor (HR) and HER2 receptor status were determined by conventional pathology using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Ki67 was assessed in a subset of patients. The overall concordance between PS and MS for luminal type cancers (A and B together) was 98%. The concordance between PS and MS for luminal A and luminal B type cancers based on the Bloom Richardson histological grade (BR) (n = 586) or Ki67 (n = 185) was low: 64% (Kappa 0.20 [95% CI 0.11⁻0.28]) and 65% (Kappa 0.22 [95% CI 0.062⁻0.37]), respectively. In this prospective study (NCT02209857) of a selection of ER+ and predominantly HER2- early-stage breast cancer patients, the additional ability of the 80-GS to distinguish between luminal, HER2-type and basal-like cancers was inhe...Continue Reading

References

Feb 1, 2000·Journal of Cellular Physiology·T Scholzen, J Gerdes
Aug 30, 2000·Nature·C M PerouD Botstein
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ander UrruticoecheaMitch Dowsett
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
May 14, 2009·Journal of the National Cancer Institute·Maggie C U CheangTorsten O Nielsen
Jun 19, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Jul 23, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M Bueno-de-MesquitaM J van de Vijver
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Sep 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenMatthew J Ellis
Jun 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Aug 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin FilipitsUNKNOWN EP Investigators
Aug 5, 2011·Breast Cancer Research and Treatment·Oscar KrijgsmanAnnuska M Glas
Oct 1, 2011·Journal of the National Cancer Institute·Mitch DowsettUNKNOWN International Ki-67 in Breast Cancer Working Group
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aleix PratCharles M Perou
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
Jul 30, 2016·Archives of Pathology & Laboratory Medicine·Ping Tang, Gary M Tse
Aug 25, 2016·The New England Journal of Medicine·Fatima CardosoUNKNOWN MINDACT Investigators
Aug 26, 2016·Breast Cancer Research and Treatment·Cornelia M FockeThomas Decker
Aug 17, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne KuijerThijs van Dalen

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02209857

Software Mentioned

BluePrint

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.